Analysis of Baseline Molecular Factors Associated With the Risk of Central Nervous System Progression Among Alectinib-Treated Patients With ALK–Positive NSCLC
Our study provided real-world evidence that patients who harbored PD-L1 TPS of 50% or higher were more likely to experience CNS progression during alectinib therapy. The association between CNS progression and breakpoint variants warrants further investigation. Our findings suggest that close monitoring and prompt intervention are crucial in prolonging the quality of life of this patient subset.
Authors
- Ruiguang Zhang
- Shaoding Lin
- Huan Yan
- Nong Yang (ORCID: https://orcid.org/0000-0003-0997-3645)
- Chunhua Zhou (ORCID: https://orcid.org/0000-0003-1543-9000)
- Xia Yang
- Yongchang Zhang (ORCID: https://orcid.org/0000-0002-6829-7176)
- Juan Yu (ORCID: https://orcid.org/0009-0002-6820-554X)
- Juan Liang
- Lianxi Song
- Qinqin Xu
- Liang Zeng (ORCID: https://orcid.org/0000-0002-9233-6665)
Institutions
- Union Hospital (HK)
- Central South University (CN)
- Changsha University (CN)
- Soochow University (CN)
- Huaian First People’s Hospital (CN)
- Zhangjiagang First People's Hospital (CN)
- Hunan Cancer Hospital (CN)
- Yantai Laiyang Central Hospital (CN)
- Qinghai Provincial Peoples Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- Huazhong University of Science and Technology (CN)
- University of South China (CN)
Publication Details
- Journal
- JTO Clinical and Research Reports
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1016/j.jtocrr.2024.100729
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province